CorrDyn

Data in Biotech

A Life Sciences , Science and Technology podcast

#6 in Life Sciences · 🇰🇷 #32 in Science · 🇰🇷

About the show

Data in Biotech is a fortnightly podcast exploring how companies leverage data to drive innovation in life sciences. Every two weeks, Ross Katz, Principal and Data Science Lead at CorrDyn, sits down with an expert from the world of biotechnology to understand how they use data science to solve technical challenges, streamline operations, and further innovation in their business. You can learn more about CorrDyn - an enterprise data specialist that enables excellent companies to make smarter strategic decisions - at www.corrdyn.com

Newest episodes

Blind Tests, Compliance Templates, and Design Over Prediction: Inside AION Labs

Nov 3, 2026 1 hr 4 min

Four rival pharma companies build AI startups together. The science is rarely what decides which ones succeed. You've built a model that works on public data. Now pharma wants a security review, a test you can't design yourself, and proof your tool fits a program they already run. Yair Benita is CTO of AION Labs, a venture studio owned by Teva, Merck, Pfizer, AstraZeneca and AWS that builds AI drug discovery companies from scratch. His career runs from immuno-oncology at Merck in the early Keytruda days to immune checkpoint discovery at Compugen and patient data work at CytoReason. Ross Katz and Yair break down the barriers between good technology and a pharma team willing to use it. You'll hear how blind validation won over skeptical chemists, why a design tool sells where a prediction stalls, and how a year of compliance work became a one-click AWS deployment. Key Takeaways A startup's model ranked a pharma compound library it had never seen, against targets it didn't know. The chemists hoped for two binders in the top 100. The results kept them testing for ten targets.Telling a team its CRISPR guide is toxic after months and $1 million of work sends them back to the start. Yair's rule: if you can predict it, you can design it.Splitting antibody discovery and optimization into two companies made scientific sense. Commercially, pharma wanted the whole step.If pharma partners can't agree on a nonclinical test for success, don't start the company. That's why AION Labs never entered drug combination. Chapter Markers 00:00 Introduction: Rival pharma companies building AI companies together 01:30 From pharmacology to computational biology 03:13 Merck and Compugen: discovering novel immune checkpoints from genome structure 07:00 Go it alone or reveal early? Lessons on proving a computational discovery 11:14 Cytoreason: deconvolving cell composition to solve pharma problems 15:18 Start with low-hanging fruit: indication selection vs. target discovery 17:30 Bu...

How Twist Bioscience Synthesizes 32 Million DNA Sequences a Day for AI Drug Discovery

Oct 14, 2026 46 min

AI can design a molecule in seconds, however someone still has to build it and test it before it means anything. You're pouring resources into AI-driven molecule design, but nobody on your team has answered the harder question: can you actually make what the model just designed? Patrick Finn is President and Chief Operating Officer of Twist Bioscience, a company writing DNA on silicon chips at a scale of roughly 32 million distinct oligonucleotides a day. Under his leadership, Twist has become the manufacturing layer behind antibody discovery, liquid biopsy, and molecular residual disease testing programs across biotech. You'll get a clear picture of what happens after an AI model produces a candidate molecule, and why the synthesis step decides whether that design ever becomes usable data. Paddy breaks down how pooled DNA synthesis and display selection turn hundreds of thousands of candidates into model feedback in weeks instead of months, and where the manufacturability gap bites hardest as AI pushes sequences into territory nature never explored. This episode covers high-throughput DNA synthesis, target enrichment for liquid biopsy, tumor-informed molecular residual disease testing, and the economics of scaling antibody discovery. It's built for data and R&D leaders investing in AI-driven drug discovery who haven't stress-tested the physical layer underneath their models, plus anyone in biotech data science curious how life sciences data pipelines actually generate their evidence. Key Takeaways Twist's silicon chip platform pushes roughly 32 million oligonucleotides through synthesis every day, and that scale is what turns a single AI-designed antibody into a dataset instead of a guess.Liquid biopsy tests need sequencing depth around 50,000x coverage to catch a signal in the noise, and target enrichment panels can cut total sequencing costs by roughly half.AI models are pushing sequence designs into territory that's genuinely hard to manufacture: homopolym...

How Standardized Cell Labeling Could Fix Biotech's Data Problem

Sep 30, 2026 1 hr 13 min

Flow cytometry can find a cell population in seconds, but naming it consistently across labs is a problem still unsolved. If you've ever tried to compare cytometry data across studies, CROs, or even two scientists in the same lab, you know the frustration: everyone gates their own way, and the same cell population ends up with three different definitions. That inconsistency is quietly limiting what AI can do with biotech data. Ryan Brinkman is VP Research Director of Flow Cytometry Bioinformatics at Dotmatics and Founding Director of SOULCAP, the Standard Ontology for Unambiguous Labeling in Cytometry and Phenotyping, built after years as an academic developing automated gating tools that kept running into the same naming problem. He's joined by Brian Wile, who is the General Manager of Flow Cytometry at KCAS Bio, a CRO that feels the cost of inconsistent labeling in client projects every day. You'll get a clear picture of how flow cytometry data moves from raw signal to labeled cell population, why that last step has resisted automation, and what a shared standard could unlock for machine learning models trained on this data. Ryan and Brian break down the gap between automated gating and consistent labeling, and why agreement, not just data volume, is what AI in biotech actually needs. This episode covers the mechanics of flow cytometry, an EVE Online citizen science project that trained a gating algorithm on hundreds of millions of human-labeled plots, and why cell population names like "Treg" or "natural killer cell" don't map to one agreed set of markers. Key Takeaways Gating automation solved half the problem: computers can now draw boundaries around cell populations, but nothing proves which name belongs on the result.A citizen science project turned hundreds of thousands of EVE Online players into an unlikely training set, collecting roughly half a billion labeled plots from people with zero biology background.The same cell type, like a regulatory T cel...

Similar podcasts

Short Wave NPR

Unexplainable Vox

Speaking of Psychology American Psychological Association

Science Friday Science Friday and WNYC Studios

The Quanta Podcast Quanta Magazine

Stuff To Blow Your Mind iHeartPodcasts

Circulation on the Run Circulation, an American Heart Association Journal

The Bio Report Levine Media Group

All episodes

Blind Tests, Compliance Templates, and Design Over Prediction: Inside AION Labs

Nov 3, 2026 1 hr 4 min

How Twist Bioscience Synthesizes 32 Million DNA Sequences a Day for AI Drug Discovery

Oct 14, 2026 46 min

How Standardized Cell Labeling Could Fix Biotech's Data Problem

Sep 30, 2026 1 hr 13 min

DrugBank CEO: Why Your AI Model Is Only Giving You Half the Answer

Sep 17, 2026 52 min

Ask a general AI model how many approved drugs hit a target, and it might tell you three when the real answer is six, sounding just as confident either way. If your team is grounding drug discovery decisions in AI output with no way to trace where the answer came from, you're one regulator's question away from a very expensive problem. Lisa Downey is CEO of DrugBank, a structured biomedical intelligence platform cited in more than 60,000 papers and used by nine of the top 20 global pharma companies. She previously built Clarivate's genomic and rare disease data business from the ground up and held leadership roles at GlobalData, giving her almost 20 years across healthcare and life sciences data. Lisa breaks down why the bottleneck in AI-driven drug discovery has shifted from data scarcity to trustworthy grounding, and what that means for teams making target identification and go/no-go calls. You'll hear how DrugBank's knowledge graph separates causation from correlation, why reproducibility matters more than speed, and what questions to ask before building a reference data layer in-house. This episode covers deterministic versus probabilistic data, human-in-the-loop versus human-over-the-loop curation, and how biopharma teams connect grounding layers to their AI agents through MCP. It's built for data and analytics leaders, R&D teams, and anyone deciding whether to build or buy their biomedical data infrastructure. Key Takeaways - A general model asked how many approved drugs hit PD-L1 will answer with total confidence, and total inaccuracy, missing half the real number without any signal that it's wrong. - Anthropic's own benchmarks found frontier models pulling public genomic data got it right as little as 17% of the time, until a deterministic tool pushed accuracy past 99%. - DrugBank moved from human-in-the-loop curation to human-over-the-loop oversight once its data was connected enough that one expert validating one relationship could cascade trust ac...

How to Identify the Blind Spots in Your Biotech's Genomic Data Before They Cost You a Drug Target

Sep 2, 2026 1 hr 10 min

Most drug discovery genomic data comes from a thin slice of the world, and that bias follows every decision downstream. Your team can run a Mendelian randomization study on 35,000 patients and still walk away with a single signal that doesn't even apply to the population you care about. If your phenotype definitions are fuzzy, more data won't save you. Erika Kvikstad is a computational biologist who led precision medicine for cardiovascular disease at Bristol-Myers Squibb, working on therapies including Camzyos for hypertrophic cardiomyopathy. She now works independently on genomic data equity, focused on how reference populations shape everything from target discovery to clinical trial recruitment. You'll get a practical look at how to evaluate real-world data vendors, why heart failure is nearly impossible to define cleanly from billing codes, and where statistical power breaks down even with tens of thousands of patients. Erika also explains how her team used AI to reconstruct missing imaging data and validate cardiomyopathy diagnoses at scale. This episode covers GWAS studies, Mendelian randomization, UK Biobank, proteome-wide analysis, and the practical gap between biobank-scale data and disease-specific cohorts. It's built for data and analytics leaders working in life sciences who need to understand where genomic bias enters their pipeline, not just that it exists. Clarification Around 57:58–58:24, in discussing the proteome-wide Mendelian randomization study, Erika moved quickly between two related findings. BTN3A2 was identified as a candidate associated with ischemic stroke and potential immune-modulatory biology. Separately, single-cell expression data helped contextualize other candidate signals, including some with enriched expression in cardiomyocyte populations. Cardiomyocyte-enriched expression was not a specific finding for BTN3A2. Chapter Markers 00:00 Whose genome are we designing drugs for 01:34 Erika's path from academic genomics to BMS...

How to Turn Single-Cell Data Into a New Class of Cell-Depleting Therapies

Aug 19, 2026 54 min

Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure. You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly leading you astray? Adam Freund is Founder and CEO of Arda Therapeutics, a biotech using single-cell sequencing to find the pathogenic cells driving chronic disease. He spent seven years as a Principal Investigator at Calico Life Sciences, building a research lab on the biology of ageing and helping grow the company from 15 to more than 200 people, and holds a PhD in Molecular and Cell Biology from UC Berkeley. You'll get a working model for how Arda's discovery engine turns single-cell and spatial transcriptomic data into causal cell targets. Adam explains why a common statistical shortcut in single-cell analysis produces disease signals that don't hold up and how cell depletion could replace daily dosing with a handful of treatments that reset the immune system. Ross and Adam cover how Arda finds pathogenic cell populations across hundreds of donors, why chi-squared tests on cell clusters can substitute cell count for donor count without anyone noticing, and how B-cell depletion therapies proved that removing a cell can beat blocking its pathway. This one is for data science leaders and computational biologists building single-cell pipelines, not listeners after a general intro to drug discovery. Key Takeaways - Chi-squared tests on cell clusters draw their statistical power from the number of cells, not the number of donors, so a single oversampled patient can produce the same p-value as a hundred-donor study. - Rituximab clears 100% of B cells from circulation yet does nothing for lupus because the disease-driving cells live in tissue, not blood, a lesson now shaping where Arda tests its own molecules. - Neighborhood analysis scores each cell by the donor identity...

Why Biotech Talks About AI But Won't Pay for the Data It Needs

Aug 5, 2026 1 hr 2 min

Everyone in biotech agrees AI needs more data. Almost no one is willing to pay for it. If you're trying to build or buy a biotech AI model, you've hit the same wall: predictive performance depends on data your budget doesn't cover, and nobody in the field seems willing to close that gap. John Androsavich runs Ginkgo Datapoints, the bio AI data arm of Ginkgo Bioworks. He trained as an RNA scientist, spent years on the pharma side deciding which technologies were worth buying, and now sells the raw biological data everyone claims to want. Ross and John get into why biotech spends a fraction of what tech spends on data, how automation dropped ADME testing to $199 a compound, and what that unlocks for drug discovery pipelines and data science in biotech more broadly. You'll hear why single-cell foundation models don't scale the way the field expected, and how GPT-5 designed its own lab experiments inside an autonomous facility. This one's for data and analytics leaders in biotech who need a clearer read on where to spend on data generation, and where the field is still guessing. It's less useful if you're after a general AI overview with no biotech specifics. Key Takeaways - One Meta investment in a data-labelling vendor outweighs a full year of AI drug discovery venture funding combined, and dwarfs the entire single-cell data market. Biotech's data spend looks nothing like tech's. - Ginkgo's ADME-1 offering runs at roughly a tenth of standard pricing, which is changing when and how much companies test. Teams are now running full tier-one panels earlier instead of triaging molecules before they've generated the negative data models need. - A recent Microsoft Research paper found single-cell foundation model learning saturates at 200,000 to 2 million cells, out of a possible 20 million. Volume alone isn't the lever people assumed it was. - GPT-5 wrote its own experimental protocols for optimising cell-free protein expression, ran them through Ginkgo's autonomous...

Beyond Language: Why Drug Discovery Needs Physical AI, Not Just Large Language Models

Jul 20, 2026 58 min

In this episode of Data in Biotech, host Ross Katz sits down with Woody Sherman, Founder and Chief Innovation Officer at PsiThera, for a conversation on why AI can transform drug discovery's paperwork and code while barely touching the hardest part of the problem: the molecules themselves. Woody's career runs through physical chemistry at MIT; over a decade at Schrödinger building tools the industry still relies on; founding Silicon Therapeutics (where his team took a small molecule STING agonist from concept to clinic in roughly three years); scaling that platform after Roivant's acquisition; and now leading PsiThera's effort to build oral small molecules for immunology targets that today are only reachable with injectable biologics. The conversation digs into why large language models excel at automation, coding, and regulatory writing but hit a wall when the task is predicting how a molecule behaves, what "physical AI" actually means as a category distinct from both LLMs and traditional physics-based simulation, and why representing molecules as quantum mechanical objects rather than text strings or 2D graphs changes what's predictable. Woody also walks through the STING program in detail, why the field's excitement over fast co-folding models like Boltz needs a strong dose of skepticism, and what it takes to build a database and team culture where chemists, biologists, and data scientists can actually understand each other. What you'll learn in this episode: >> Why the contradiction of "AI is transforming drug discovery" and "drugs still take a decade and billions of dollars" can both be true at once. >> How Silicon Therapeutics engineered a small molecule STING agonist to dimerize itself through a quantum mechanical interaction that had never been designed for before. >> What "physical AI" means as a new category built on embeddings from orbital-level, quantum mechanical representations of molecules, rather than language tokens or force-field simulations...

Synthesizable by Design: Rethinking AI's Role in Small Molecule Drug Discovery

Jun 17, 2026 59 min

In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul brings four decades of experience across what became GSK, Pfizer, and a series of Oxford-area spinouts and has shepherded a compound all the way to a marketed drug. That perspective gives him a particular kind of skepticism toward AI results that look too good to be true because he's done the work of checking whether they are. The conversation moves through synthesizability as a first-class constraint, why chemistry has proven so much harder for AI than biology, how 3D molecular representation gets closer to the physics that actually matters, and what rigorous multi-parameter optimization looks like when you're trying to kill cancer cells and drug-resistant bacteria at the same time. What you'll learn in this episode: >> Why synthesizability is chronically underestimated and why changing a single atom in a structure can take a molecule from trivially easy to make to practically impossible >> How Oxford Drug Design constrains the generative search to reaction schemes and purchasable building blocks, and why that chemical space is still so vast that novelty is not meaningfully sacrificed >> Why most generative AI models learn from a 2D string representation of a molecule; two steps removed from the 3D physics that govern how a drug actually binds to its target >> How Bayesian optimization over reagent space, rather than molecular space, allows an active learning loop to focus on the structural patterns associated with activity >> Why benchmarking complex models against simple ones is the discipline that exposes false correlations and why Paul and his co-authors were able to recover the Halicin result using methods decades older than deep learning >> What a pharma company...

From Tissue to Mechanism to Decision: Building AI for Computational Oncology

Jun 2, 2026 46 min

In this episode of Data in Biotech, host Ross Katz sits down with Arvind Rao, Professor of Computational Medicine and Bioinformatics at the University of Michigan, for a discussion on the gap between what biomedical AI can do and what it can reliably be trusted to do in clinical practice. Arvind's research sits at the intersection of computational oncology and AI governance and his lab works across H&E histopathology, multiplex immunofluorescence, spatial transcriptomics, and single-cell RNA sequencing, not just to build predictive models, but to understand the full lifecycle from data to model to inference, and to ask where that lifecycle can be trusted and where it can't. The conversation moves through two of his recent papers on SPIFEE, a graph-based framework that replaces scalar interaction scores in the tumor microenvironment with spatially resolved functional representations, and a multimodal framework that traces a path from stained tissue slides to nominated drug targets via morphological pattern discovery and spatial transcriptomic mapping. What you’ll learn in this episode: >> Why the field's central failure is not algorithmic but translational and the gap between a model that performs well on a benchmark and one that can be consistently trusted in a high-stakes clinical setting >> How SPIFEE replaces the conventional scalar edge representation of cell-cell interactions in the tumor microenvironment with spatially resolved functional edges >> How Arvind's multimodal framework moves from H&E pathology slides labeled with clinical outcomes, through morphological pattern discovery via multiple instance learning, to spatial transcriptomic mapping, to the nomination of molecular mechanisms and actionable drug targets >> Why Goodhart's Law applies directly to foundation model evaluation in biology >> What the AI literacy gap costs when it goes unaddressed in healthcare and pharma organizations Meet our guest: Arvind Rao is a Professor of Computat...

Cavities in the Data: Building FDA-Cleared AI for Dental Imaging with Overjet

May 13, 2026 58 min

In this episode of Data in Biotech, host Ross Katz sits down with Sadegh Salehi, Director of Research and Principal Scientist at Overjet, to explore what rigorous model evaluation actually looks like when the stakes are clinical. Overjet builds FDA-cleared vision models that detect and quantify dental disease across billions of X-ray images from thousands of practices - a data problem with a staggering number of dimensions. Thirty-two teeth per adult patient, each with different morphology. Multiple image types capturing different anatomy. Fifteen to twenty sensor manufacturers producing perceptually distinct images, each with different contrast, resolution, and noise characteristics. And disease severity distributions ranging from barely visible early-stage decay to obvious pathology. Sadegh walks through what it takes to evaluate models responsibly across all of those dimensions and discusses why aggregate metrics like F1 score can mask catastrophic failures on specific subgroups, how models find and exploit shortcuts in training data, and why the same flawed sampling that creates gaps in your training set also creates them in your test set. He also traces Overjet's architectural evolution from over twenty narrow task-specific models to a single foundation model they call Unity, explains how treatment plan procedure codes provide a noisy but real production feedback signal, and describes how Overjet became one of the first companies to secure the FDA's Predetermined Change Control Plan (a framework that allows model updates without filing a new clearance each time.) What you’ll learn in this episode: >> Why aggregate evaluation metrics are insufficient for high-stakes medical AI >> How models exploit shortcuts in training data: if all images from a rare sensor in the training set happen to be healthy, the model doesn't learn to read that sensor, it learns that the sensor means healthy, bypassing the visual task entirely and producing systematic false ne...

Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive

Apr 30, 2026 42 min

In this episode of Data in Biotech, host Ross Katz sits down with Jesse Johnson, founder of Merelogic, a software consulting firm specializing in data infrastructure for biotech organizations. Jesse brings a rare perspective to the conversation: having built data systems at Google where engineers control the data collection function end to end, before moving into biotech, where the biology does what it wants and bench scientists, not engineers, generate the data. The result is a grounded, pragmatic take on one of the most consequential and underappreciated questions in life sciences right now: as bio foundation models fundamentally change the value equation for experimental data, are biotech labs structured to capture that value? Jesse argues the answer is usually no and that the fix is less technical than most assume. It doesn't require a production-grade data pipeline or a cloud architecture. It requires lightweight, human-readable standard operating procedures, clear expectations between computational and wet lab teams, and a data strategy designed not just for the questions you're asking today, but for the ones you don't yet know you'll need to ask. What you’ll learn in this episode: >> Why the transition from tech to biotech requires a fundamental reset of assumptions about data infrastructure and why the biggest difference isn't technical, it's organizational. >> How bio foundation models have flipped the value equation for experimental data by reducing the cost of organizing it while dramatically increasing the potential return >> How the strategic value of proprietary data is evolving in the biotech ecosystem, from Tahoe Therapeutics building an acquirable single-cell dataset to Eli Lilly's Lowe lab using data as currency for partnerships >> Why electronic lab notebooks aren't going anywhere and how the real question facing biotech software teams isn't whether to use an ELN, but how to balance schema rigidity against the flexibility required for...

Markus Gershater on Why Experimental Design in Biotech is Broken and How to Fix It

Apr 15, 2026 41 min

This week, we're delighted to be joined by Markus Gershater, Chief Scientific Officer and CoFounder of Synthace - a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. Host Ross Katz speaks with Markus on what’s broken about: What’s broken about how laboratories across the globe run biological experiments at scaleThe opportunity that exists for researchers in striving to achieve experimental design automation processesWhy, as an industry, we must move towards implementing infrastructure that enables multifactorial experiments versus one-factor experimentsAnd the role of AI in making sense of complex systems. --- If you’re a biotech company struggling to transform your business with data, CorrDyn can help. Whether you need to supplement existing technology teams with specialist expertise or launch a data program that lays the groundwork for future internal hires, you can partner with Corrdyn to unlock the potential of your business data - today. Visit connect.corrdyn.com/biotech to learn more. --- Data in Biotech is a fortnightly podcast exploring how companies leverage data to drive innovation in life sciences.

Data Science and Diagnostic Models - the What, Why and How with Michelle Wiest

Apr 15, 2026 44 min

This week, we're delighted to be joined by Michelle Wiest, Director of IVD Biostatistics at Freenome - a high-growth biotech company that creates tools to help prevent, detect, and treat disease. Host Ross Katz speaks with Michelle on the use of biostatistics in the field of diagnostics, what biases can corrupt diagnostic tests and how to catch them early, the different types of data sets that are being used to develop diagnostic models and how to prepare to present data to regulatory bodies such as the FDA. --- If you’re a biotech company struggling to transform your business with data, CorrDyn can help. Whether you need to supplement existing technology teams with specialist expertise or launch a data program that lays the groundwork for future internal hires, you can partner with Corrdyn to unlock the potential of your business data - today. Visit connect.corrdyn.com/biotech to learn more. --- Data in Biotech is a fortnightly podcast exploring how companies leverage data to drive innovation in life sciences.

The Patient is Not a Document: Foundation Models for Biomedical AI with Standard BioModel

Apr 15, 2026 49 min

In this episode of Data in Biotech, host Ross Katz sits down with Kevin Brown, co-founder of Standard BioModel, to explore one of the most ambitious projects in biomedical AI, building a multimodal foundation model that represents the full complexity of a patient across time. Drawing on a career spanning brain-computer interfaces, computer-aided diagnosis at Siemens Healthineers, and oncology data science at Bristol Myers Squibb, Kevin shares the scientific and philosophical journey that led him to a single conviction: a patient is not a document. Rather than reducing a patient to clinical notes, ICD-10 codes, or isolated test results, Standard BioModel's approach maps every available modality - CT imaging, digital pathology, genomics, EKGs, longitudinal EHR data - into a shared latent space, and models how that patient moves through time. The result is a framework designed not just for prediction, but for counterfactual reasoning, clinical trial matching, and personalized intervention, with open-source models already being validated across leading academic medical centers. What you’ll learn in this episode: >> Why reducing a patient to text - clinical notes, radiology reports, genomic assay summaries - and how mapping multimodal data into a shared latent embedding space preserves information that never makes it into the written record >> How Standard BioModel's temporal architecture models patients as trajectories through an abstract embedding space rather than static snapshots, enabling counterfactual reasoning about the likely impact of interventions on a patient's future health trajectory >> Why no single foundation model can own every clinical vertical and how building a highly generalizable base model that facilitates downstream fine-tuning is a more defensible and scalable strategy than building narrow, application-specific models >> How the model handles missing modalities in real-world clinical settings, and why the architecture is designed to fun...

Physics, Free Energy, & Drug Discovery: Inside Schrödinger's Computational Platform

Apr 1, 2026 57 min

In this episode of Data in Biotech, Ross Katz sits down with Robert Abel, Chief Scientific Officer of the Platform at Schrödinger, to explore how physics-based computational modeling is transforming drug discovery. Robert unpacks why machine learning alone isn't enough to navigate the vast complexity of chemical space - an estimated at 10⁶⁰ possible drug-like molecules - and how integrating atomistic simulations with ML creates a more accurate, reliable, and scalable approach to identifying viable drug candidates. From free energy perturbation calculations to generative AI, Robert offers a rare inside look at how Schrödinger's technology platform is accelerating the path from target identification to clinical candidate and where the field is headed next. What you’ll learn in this episode: >> Why chemical space (~10⁶⁰ molecules) makes purely data-driven ML approaches fundamentally insufficient for drug discovery, and how physics-based sampling solves the training data problem >> How free energy perturbation (FEP) calculations enable quantitative prediction of protein-ligand binding affinities at near-experimental accuracy (~1.2 kcal/mol RMSE) >> How Schrödinger's active learning framework combines physics-based simulations and ML to triage billions of candidate molecules before committing to wet lab synthesis >> Why Schrödinger operates across three business lines; software licensing, collaborative programs, and proprietary drug discovery and how each strengthens the underlying technology platform >> Where the next frontiers lie: routine anti-target selectivity profiling, retrosynthetic AI integration, and the expanding role of generative ML in de novo molecular design Meet our guest: Robert Abel is Chief Scientific Officer, Platform at Schrödinger, where he helps lead the scientific direction behind computational approaches that support modern drug discovery and molecular design. With a PhD in Chemical Physics from Columbia University and a deep backgroun...

AI in biotech: separating hype from reality with Ben Locwin

Mar 11, 2026 30 min

In this episode of Data in Biotech, host Ross Katz sits down with Ben Locwin, Vice President at Reliant Life Sciences, to explore the evolving landscape of artificial intelligence in biotechnology. Join us as we discuss why nearly every biotech claims to use AI but few actually do, examine successful applications like AlphaFold, and explore the challenges of implementing AI across drug development, manufacturing, and regulatory processes. Ben shares insights on maintaining healthy skepticism, understanding data provenance, and looking ahead to what this year may bring for AI in life sciences. What you’ll learn in this episode: >> The AI hype problem in biotech and why most companies claim to use AI but few actually do. >> AlphaFold as the gold standard and how DeepMind's protein structure prediction model represents the most successful application of AI in biotech >> Data quality over algorithmic sophistication and the critical importance of data provenance, examining primary sources, and understanding that data quality matters more than the complexity of the AI model >> The balance between optimism and evidence-based decision-making, distinguishing between sophisticated AI and advanced statistical modeling Meet our guest: Ben Locwin is a healthcare and life sciences executive and medical scientist known for helping bring pharmaceuticals, vaccines, and medical devices to market faster and with higher quality. A TEDx speaker and seasoned leader, he’s worked across major biotech hubs and has deep expertise in global regulatory pathways, having collaborated with the FDA, EMA, MHRA, PMDA, and more. Connect with Ben Locwin on LinkedIn About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn Connect with us: Follow the podcast for more insightful discussions on...

3D Printing Therapeutics at Scale with Aprecia Pharmaceuticals

Feb 25, 2026 49 min

In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world’s first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you b...

Success-Driven Drug Discovery with OpenBench CEO James Yoder

Feb 11, 2026 53 min

In this episode of Data in Biotech, host Ross Katz sits down with James Yoder, Founder and CEO of OpenBench, to unpack a radical new approach to early-stage drug discovery. James shares how OpenBench's "success-driven" model shifts risk away from biotech partners by only charging for validated hits. They dive deep into computational screening, molecular modeling, and the company's evolving tech stack that's making hit discovery smarter and more accessible. Discover how data, AI, and strategic collaboration are redefining biotech R&D. What you'll learn in this episode: >> Why OpenBench moved away from SaaS to a success-based service model >> How their computational platform predicts binding affinity and screens trillions of compounds >> The role of data flywheels and ML in improving drug discovery success rates >> Real-world case studies from biotech collaborations >> How OpenBench evaluates druggable targets in one week Meet our guest James Yoder is the Founder and CEO of OpenBench. With a background in statistics, data science, and applied machine learning, he leads OpenBench's mission to deliver validated drug discovery hits through computational innovation and a success-driven business model. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with James Yoder on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Brant Peterson on Valo Health’s patient-first approach to drug discovery

Jan 29, 2026 52 min

Brant Peterson, Vice President & Fellow at Valo Health, joins Data in Biotech to explore how his team leverages real-world data, genetic insights, and machine learning to de-risk drug discovery. From building causal DAGs to identifying patient subtypes in neurodegenerative diseases like Parkinson’s, this episode dives deep into a patient-first, data-driven approach to biomedical innovation. What You'll Learn in This Episode: >> How Valo Health uses real-world evidence and EHR data to prioritize drug targets earlier in the development pipeline. >> Why integrating wet lab experiments and causal DAGs accelerates therapeutic validation. >> The importance of genetic pleiotropy and Mendelian randomization in refining disease hypotheses. >> How Valo Health identifies high-impact patient subgroups in neurodegenerative diseases like Parkinson’s and Alzheimer’s. >> Where machine learning models succeed and fall short, in uncovering mechanisms of disease from sparse longitudinal data. Meet Our Guest Brant Peterson is Vice President & Fellow in Data Science at Valo Health. He brings deep expertise in genetics, computational biology, and biomedical innovation. Formerly a Distinguished Data Scientist at Valo and Computational Biologist at Novartis, Brant focuses on leveraging patient-centric data to drive causal discovery in drug development. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Brant Peterson on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and hea...

Inside Dash Bio’s productized CRO model with Ander Tallet

Jan 14, 2026 43 min

Ander Tallet, co-founder and COO of Dash Bio and CEO of DigitalRadius, joins Ross Katz to discuss transforming the traditional CRO model through automation, transparency, and productization. Drawing on deep experience from Moderna, Science Exchange, and his leadership roles in digital transformation, Ander shares how Dash Bio is slashing turnaround times, improving data quality, and simplifying procurement for biotech companies. This episode unpacks the future of CRO services, strategic procurement, and the power of operational innovation in biotech. What you'll learn in this episode: >> Why traditional CRO models hinder speed and transparency in biotech >> How Dash Bio delivers 90% faster turnaround through automation >> What productizing CRO services really means for the customer experience >> How regulatory requirements shape innovation in clinical bioanalysis >> Why investor buy-in requires solving real, painful problems in biotech Meet our guest Ander Tallett is the co-founder and COO of Dash Bio and the CEO of DigitalRadius, where he leads digital transformation initiatives as one of the largest Smartsheet partners in the ecosystem. He previously served as Chief Strategy Officer at Science Exchange and co-founded Block Mill Capital, a B2B SaaS-focused investment fund shaped by his experience evaluating and implementing more than 100 SaaS platforms. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with Ander Tallet on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven sol...

From discovery to delivery: AI’s impact on nanomedicine

Dec 31, 2025 46 min

In this episode of Data in Biotech, Ross Katz chats with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are revolutionizing nanomedicine. They explore the use of AI in drug discovery, formulation, manufacturing, and clinical development, highlighting how data-driven strategies are improving safety, reducing costs, and enabling more personalized therapies in the biotech space. What you'll learn in this episode: >> How AI and ML reduce costs and increase success rates in nanomedicine development. >> Key challenges in nano drug delivery and how machine learning helps overcome them. >> How HTD Biosystems' iFormulate platform speeds up formulation with predictive modeling. >> How wearables and real-time data are reshaping clinical trial design. >> The future of personalized and automated drug delivery systems. Meet our guest Mitra Mosharraf is the Chief Scientific Officer at HTD Biosystems and co-founder of Engimata Inc. With 20+ years of experience, she leads innovation in biologics, nanomedicine, and lipid-based delivery systems. Mitra is a recognized thought leader in pharmaceutical sciences. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Mitra Mosharraf on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Jaidev Chakka on building the future of bioprinted medicine

Dec 26, 2025 45 min

In this episode of Data in Biotech, Ross Katz chats with Jaidev Chakka, Principal Scientist at the University of Mississippi School of Pharmacy, about how 3D bioprinting and AI are reshaping pharmaceutical manufacturing. They explore the development of custom scaffolds for tissue engineering, the integration of gene delivery systems, and how data-driven approaches are enabling smarter, more scalable solutions in personalized medicine. What you'll learn in this episode: >> How 3D printing is enabling customized bone scaffolds and regenerative therapies >> The role of AI in optimizing pharmaceutical 3D printing parameters >> How organoids can act as micro-organs for testing and computation >> The promise and challenge of personalized, on-demand drug manufacturing >> Why collaboration between data scientists and biopharma researchers is critical Meet our guest LR Jaidev Chakka is a Principal Scientist at the University of Mississippi School of Pharmacy, pioneering 3D bioprinting, drug delivery, and organoid research to revolutionize patient care and pharma manufacturing. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Jaidev Chakka on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

From screening to IND: How Veloxity accelerates critical drug decisions

Dec 22, 2025 25 min

In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions. What you'll learn in this episode: >> Why "speed with purpose" is essential for bioanalytical CROs supporting biotech and pharma clients >> The benefits and challenges of working with peptides and GLP-1 receptor agonists >> How the SCIEX 8600 enhances detection of low-concentration analytes Meet our guests Isa Kupke is Scientist II at Veloxity Labs, where she specializes in mass spectrometry and method development for preclinical and regulated bioanalytical programs. She also co-founded Blyde Botanics, bridging plant-based science and product development. Callie Celichowski is Senior Director of Business Development at Veloxity Labs, with over two decades in the pharmaceutical and CRO space. She's recognized for building strategic client partnerships and driving rapid, data-driven decision-making. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Isa Kupke on LinkedIn Connect with Callie Celichowski on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into brea...

Revolutionizing bioanalysis with high-resolution mass spec

Dec 15, 2025 32 min

In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science. What you'll learn in this episode: >> Why traditional mass spectrometry falls short in modern bioanalysis >> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs >> The role of high-resolution systems in detecting complex drug metabolites >> How automation tools are streamlining workflows for bioanalytical scientists >> The complementary role of AI and ML in mass spec data analysis Meet our guest Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Eshani Galermo on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Mastering solubility and stability in drug development with Serán BioScience

Dec 3, 2025 51 min

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren’t yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he’s especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-dri...

Applying ML/AI to Drug Development with Anil Kane

Nov 26, 2025 35 min

Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation. What You'll Learn in This Episode: >> How predictive modeling eliminates trial-and-error in drug formulation >> The role of AI/ML in improving manufacturing efficiency and reducing downtime >> How Thermo Fisher’s ASAP program accelerates stability testing >> The future of digital transformation in pharma, including OpenAI partnerships >> Where human expertise fits in a digitally enhanced development pipeline Meet Our Guest Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Anil Kane on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Streamlining bioanalytical workflows with Watson LIMS and Thermo Fisher

Nov 20, 2025 49 min

In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow. >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in da...

Scaling AI infra in biotech with Saturn Cloud and Nebius

Nov 5, 2025 52 min

Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences. What You'll Learn in This Episode: >> Why AI workloads in biotech demand specialized infrastructure >> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences >> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI >> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost >> Strategies for deploying, optimizing, and managing large-scale AI models Meet Our Guests Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction. Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Hugo Shi on LinkedIn Connect with IIya Burkov on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healt...

The Future of Co-Folding and Federated Learning with Apheris

Oct 22, 2025 49 min

Robin Rohm, CEO and Co-Founder of Apheris, joins Ross Katz to explore how federated learning is unlocking secure, cross-company collaboration in pharma. Discover how Apheris is enabling biopharma leaders to train cutting-edge co-folding models without sharing sensitive data, why AlphaFold 3 wasn’t enough, and what OpenFold 3 means for the future of AI in drug discovery. What You'll Learn in This Episode >> Why federated learning is a game-changer for pharma data sharing and AI-driven research >> How OpenFold 3 builds on AlphaFold’s legacy to solve the protein-ligand interaction challenge >> The role of structural benchmarking in model development and validation >> How Apheris enables privacy-preserving collaboration between major pharma players >>The importance of high-quality, proprietary datasets in advancing co-folding model accuracy Meet Our Guest Robin Rohm is the CEO and Co-Founder of Apheris, a leader in federated data networks for life sciences. With a background in mathematics and computational genomics, Robin is advancing secure AI collaboration in pharma and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Robin Roehm on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Automating biopharma knowledge work with Convoke

Oct 1, 2025 56 min

What if biotech teams could automate the most information-intensive parts of bringing a drug to market? In this episode of Data in Biotech, host Ross Katz speaks with Convoke co-founders Alex Telford and Maged Ahmed about building an AI-native knowledge acquisition and curation system for biopharma. Learn how they're transforming clinical research, regulatory writing, and competitive intelligence using LLMs, semantic search, and scalable data infrastructure. What You'll Learn in This Episode: >> How Convoke unifies public and private biotech data into a single workspace for smarter decision-making >> Why structured outputs and semantic layers are key to high-quality AI-driven insights >> Real-world use cases including clinical trial design, competitive landscape analysis, and regulatory documentation >> How feedback loops and model evaluations drive product reliability and user trust >> The future of AI in biotech: continuous decision-making and multimodal intelligence Meet Our Guests Alex Telford is Co-Founder and CEO of Convoke, an AI-native OS transforming drug development workflows. His background in life sciences consulting drives his mission to unify data and streamline outputs like clinical documents and regulatory submissions. Maged Ahmed is Co-Founder of Convoke and a former AI lead at Applied Intuition. He brings deep data infrastructure expertise to biotech, aiming to reduce friction in regulated environments by automating knowledge generation. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Alex Telford on LinkedIn Connect with Maged Ahmed on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enj...

How Eli Lilly’s new platform TuneLab codevelops AI models with biotech

Sep 17, 2025 40 min

Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly’s billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D. What You'll Learn in This Episode: >> How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data >> What federated learning means for IP protection and collaborative data sharing in biotech >> Which two key use cases are driving TuneLab’s impact today: small molecule ADME and antibody developability >> How TuneLab’s early adopters like Firefly Bio and Superluminal are shaping the platform’s evolution >> Why generalizability—not just accuracy—is the true power of collaborative AI in drug development Meet Our Guest Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Aliza Apple on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Inside Merck's Computational Biology Approach with Jesper Ryge

Sep 3, 2025 46 min

In this episode of Data in Biotech, host Ross Katz talks with Jesper Ryge, Director of Computational Biology at Merck Germany. Jesper shares his journey from neuroscience labs to leading computational teams, offering deep insights into disease modeling, target discovery, and multi-omics integration. Discover how AI and spatial transcriptomics are shaping the future of pharma R&D. What You'll Learn in This Episode >> How single-cell and spatial transcriptomics enhance disease mechanism discovery >> Why data integration and knowledge graphs are critical for target validation >> How computational biology teams interface with wet lab research >> What makes Merck Germany's data strategy unique in biotech >> How generative AI is changing how pharma interprets complex datasets Meet Our Guest Jesper Ryge is Director of Computational Biology at Merck Germany. A biophysicist by training, he brings deep expertise in neuroscience, single-cell analysis, and bioinformatics to pharmaceutical R&D. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about MerckConnect with Jesper Ryge on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Where Biotech Innovation Really Happens: 50th Episode Special with Wolfgang Halter, Jacob Oppenheim, and Dave Johnson

Aug 20, 2025 31 min

To mark our 50th episode, host Ross Katz brings back three visionary leaders—Dave Johnson (Dash Bio), Wolfgang Halter (Merck Life Science), and Jacob Oppenheim (RAVen)—together for a reflection on the evolution of biotech. They unpack the realities behind AI hype, the future of data-driven innovation, and what’s really changing in drug development. What You'll Learn in This Episode: >> Where real innovation is emerging across startups, big tech, and academia >> The biggest misconceptions about data in biotech—and why they persist >> What it takes to build trust in AI-powered biotech tools >> Why progress in biotech depends as much on execution as it does on breakthroughs >> How industry veterans see the future of automation, regulation, and global competition Meet Our Guests Dave Johnson is CEO and Co-Founder of Dash Bio and former Chief Data & AI Officer at Moderna. He’s pioneering automation in clinical bioanalysis to accelerate drug development. Wolfgang Halter leads Data Science at Merck Life Science, developing tools like BayBE to optimize R&D through smarter data modeling and open-source innovation. Jacob Oppenheim is a Venture Partner at RAVen and co-founder of Fresnel. With a PhD in Biological Physics, he champions the transition to digital-native biopharma. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Dave Johnson on LinkedIn Connect with Wolfgang Halter on LinkedInConnect with Jacob Oppenheim on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions...

How BioRaptor is Modernizing Bioprocessing Workflows

Jul 31, 2025 49 min

In this episode of Data in Biotech, Yaron David, CTO and Co-Founder of BioRaptor, joins host Ross Katz to explore how biotech companies can gain a holistic view of bioprocessing through real-time data integration, visualization, and modeling. Learn how BioRaptor’s full-stack platform helps scientists replace clunky spreadsheets with actionable insights—accelerating experiments and optimizing yields. What You'll Learn in This Episode: >> Why Excel is holding back innovation in bioprocessing labs >> How BioRaptor enables holistic bioprocess understanding across experiments >> The role of virtual sensors in enhancing real-time data visibility >> How BioRaptor drives ROI by onboarding customers in weeks, not months >> The difference between operational and optimization AI in biotech Meet Our Guest Yaron David is CTO and Co-Founder of BioRaptor, an AI-powered analytics platform transforming bioprocess data into scientific insights. With an MD and PhD in neuroscience, he blends medical, software, and startup experience to revolutionize data infrastructure for biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about BioRaptorConnect with Yaron David on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Modernizing Clinical Data Analysis with Jesse Paquette

Jul 11, 2025 45 min

In this episode of Data in Biotech, Jesse Paquette, co-founder and Chief Science Officer of Tag.bio, joins Ross Katz to explore how data mesh architecture and FAIR data principles are transforming clinical and research workflows in life sciences. From harmonizing legacy systems to enabling AI-readiness, Jesse shares how Tag.bio empowers domain experts to make data-driven decisions faster and more effectively. What You'll Learn in This Episode: >> How Tag.bio leverages data mesh and FAIR principles to democratize biomedical data access. >> The challenges biotech firms face with legacy infrastructure and clinical trial data. >> The importance of harmonized, version-controlled data products in AI-driven research. >> Why smaller pharma and life sciences firms benefit most from Tag.bio’s agile platform. Meet Our Guest Jesse Paquette is the co-founder and Chief Science Officer of Tag.bio, where he leads scientific strategy for AI-powered analytics. With over two decades in life sciences, he specializes in building tools that help researchers interpret complex biomedical data independently. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Tag.bioConnect with Jesse Parquette on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Building Scalable Data Platforms for Spatial Biology with Kenny Workman of LatchBio

Jun 25, 2025 55 min

In this episode of Data in Biotech, Ross Katz sits down with Kenny Workman, co-founder and CTO of LatchBio, to unpack how biotech’s data infrastructure must evolve to meet the demands of next-gen assays. From scalable workflows to high-performance visualization tools, Kenny breaks down the shift from traditional biotech to a future defined by data-driven research and agile cloud platforms. What You'll Learn in This Episode: Why spatial biology and high-throughput assays require new data infrastructure strategiesHow LatchBio’s five core components streamline molecular data processingThe challenges of selling into biotech vs. solution providers and the strategic pivot LatchBio made to address thisHow large language models are revolutionizing public data curation for biotechsWhy scientific innovation demands better tech adoption across the industry Meet Our Guest Kenny Workman is co-founder and CTO of LatchBio, a company transforming biological data infrastructure. A UC Berkeley alum, Kenny brings deep expertise in bioengineering, machine learning, and cloud systems. He was named to Forbes' 2023 "30 Under 30" list for his contributions to computational biology. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Latch BioConnect with Kenny Workman on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Solving Chronic Disease with Life Insurance and Data Featuring Jeremy Shane

Jun 11, 2025 1 hr 0 min

Entrepreneur Jeremy Shane joins host Ross Katz to discuss Life for Health, a revolutionary framework aiming to tackle chronic disease through the integration of life insurance, longitudinal data, and preventative care. From drug discovery feedback loops to outcomes-based pricing, Shane outlines a bold new path for biotech and healthcare convergence. What You'll Learn in This Episode: Why today's healthcare system fails chronic disease patients and how Life for Health aims to fix it.How longitudinal data and life insurance can realign healthcare incentives for better outcomes.The economic logic behind outcomes-based annuity pricing for breakthrough drugs like GLP-1s.What biotech companies gain from a proactive, participant-driven health model.How clinical trials could transform through pre-qualified data-rich populations. Meet Our Guest Jeremy Shane, Venture Partner at NextGen Venture Partners, is a healthcare innovator focused on chronic disease. With leadership experience at HealthCentral, WebMD, and 2U, he now pioneers Life for Health, blending life insurance with preventative care to realign incentives and extend health span. Life for Health, the book, will be released in July 2025. To learn more about Life For Health or get involved, go to www.lifeforhealth.com About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Jeremy Shane on LinkedIn or on Twitter @jeremylshane Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into b...

How Etiome Is Redefining Preemptive Medicine with Scott Lipnick

May 29, 2025 58 min

In this episode of Data in Biotech, host Ross Katz sits down with Scott Lipnick, Co-Founder and President of Etiome, to explore how preemptive medicine is changing the way biotech approaches therapeutic modeling and intervention. Discover how Etiome’s recently launched, AI-driven platform is built to detect disease earlier, identify precise biomarkers, and create stage-specific treatments—all before symptoms arise. It’s a visionary approach to healthcare focused on preserving health, not just managing illness. What You'll Learn in This Episode: Why Scott Lipnick believes the future of medicine lies in preemptive care.How Etiome uses AI to map disease progression at the cellular level.The role of biomarkers in identifying disease before symptoms surface.How Etiome applies its Temporal Biodynamics platform across diseases.What venture creation looks like at Flagship Pioneering. Meet Our Guest Scott Lipnick is the Co-founder and President of Etiome. At the forefront of preemptive medicine, Scott’s work focuses on predicting disease progression and delivering personalized, early-stage interventions using cutting-edge AI and molecular tools. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about EtiomeConnect with Scott on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Transforming Houseplants with Synthetic Biology with Patrick Torbey

May 14, 2025 47 min

In this episode of Data in Biotech, host Ross Katz speaks with Patrick Torbey, CEO and Co-Founder of Neoplants, about using genetic engineering and microbiome innovation to tackle indoor air pollution. Patrick explains how Neoplants is turning everyday houseplants into powerful air purifiers using synthetic biology, offering insights into VOC degradation, enzyme pathways, and data-driven R&D. What You'll Learn in This Episode: How genetically modified plants and microbiomes can reduce indoor air pollution by targeting VOCs like formaldehyde and benzeneThe scientific and engineering challenges of modifying indoor plants at the genomic levelWhy data-driven testing and simulation are critical to optimizing plant function and user impactThe role of synthetic biology in creating sustainable, scalable biotech productsPatrick’s vision for solving climate challenges through engineered plant ecosystems Meet Our Guest: Patrick Torbey is the CEO and Co-Founder of Neoplants, a Paris-based biotech startup engineering plants to purify indoor air. With a PhD in genetic editing and deep expertise in synthetic biology, Patrick leads Neoplants in building functional, aesthetically unique, and sustainable plant systems for the future. About The Host: Ross Katz is the Principal Data Scientist at CorrDyn. He brings decades of experience across biotech, energy, and non-profit sectors, with a focus on building smarter data systems, machine learning pipelines, and actionable insights for complex industries. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about NeoplantsConnect with Patrick Torbey on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!

How Phage Therapy is Scaling to Meet Antibiotic Resistance with Jessica Sacher

Apr 30, 2025 59 min

Phage therapy is stepping into the spotlight as antibiotic resistance rises - and Jessica Sacher is helping lead the charge. In this episode, Ross Katz speaks with Jessica, Co-Founder of Phage Directory and Staff Scientist at Stanford, about sourcing phages, operationalizing therapy, and predicting efficacy through data. This conversation explores how personalized phage therapy works, its scalability, and the data challenges shaping its future. What You'll Learn in This Episode: Why phage therapy is a promising solution to antibiotic-resistant infectionsHow Phage Directory connects researchers and clinicians to accelerate treatmentWhat operational hurdles exist in scaling personalized phage productionHow data science is being applied to predict effective phage-bacteria matchesWhy building infrastructure and awareness is essential to adoption in clinical care Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Phage DirectoryConnect with Jessica on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Resources Mentioned: Why Language Itself Might Be Holding Back AI – by Ross Katz: https://www.linkedin.com/pulse/why-language-itself-might-holding-back-ai-ross-katz-rcl9e/?trackingId=Y6%2FH45W%2BxImfl%2By2geB6%2Bg%3D%3DBacteriophage Therapy for Multidrug-Resistant Infections – PubMed: https://pubmed.ncbi.nlm.nih.gov/40026251/Cystic Fibrosis Australia and Phage Australia Survey – medRxiv: https://www.medrxiv.org/content/10.1101/2024.05.14.24307275v1Phage Directory: https://phage.directory/

Targeting Transcription Factors with AI, featuring Will Fondrie from Talus Bio

Apr 16, 2025 46 min

How do you drug the undruggable? In this episode of Data in Biotech, Ross Katz sits down with Will Fondrie, Head of Data Science and Engineering at Talus Bio, to explore how machine learning, mass spectrometry, and innovative computational models are transforming drug discovery. Learn how Talus Bio is targeting transcription factors—once considered out of reach—with scalable, high-impact data science. What You'll Learn in This Episode Why transcription factors are historically hard to drug and how Talus Bio is changing thatHow mass spectrometry offers high-throughput, unbiased views of protein-DNA interactionsThe role of recommender systems in prioritizing compound testingStrategies for balancing build vs. buy in data infrastructure at scaleWhy open-source software is essential for scientific transparency and progress Links: Find out more about Talus Bio: https://talus.bioConnect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with Will Fondrie on LinkedIn: https://www.linkedin.com/in/wfondrie/ Meet Our Guest Will Fondrie is the Head of Data Science and Engineering at Talus Bio, a biotech company pioneering the development of small molecule drugs targeting transcription factors. With a PhD in molecular medicine and a background in proteomics, Will brings deep expertise in computational biology, machine learning, and scalable data systems. About the Host Ross Katz is the Principal and Data Science Lead at CorrDyn. He hosts Data in Biotech to spotlight innovative thinkers and data-driven leaders pushing the boundaries of biotechnology. Enjoying the show? If you liked this episode, consider sharing it with a colleague and exploring more conversations at Data in Biotech. Your support helps us keep delivering expert insights on the future of biotech. Sponsored by CorrDyn This episode is brought to you by CorrDyn, a leader in data-driven solutions for biotech and healthcare. Learn more at CorrDyn.

Decoding the Dark Proteome: Biological Insights for Pharma with Dr. Jonathan Usuka from Sapient

Apr 2, 2025 46 min

In this episode of the Data and Biotech Podcast, host Ross Katz sits down with Dr. Jonathan Usuka to discuss Usuka’s extensive background in bioinformatics and genomics, leading to his current role as CEO of Sapient. The conversation dives into the importance of deep molecular characterization of diseases, the role of proteomics and metabolomics in drug discovery, and the gaps between real-world data and clinical trial data. As a leader with a small but impactful team, Jonathan discusses the complexities of the dark proteome and metabolites, emphasizing the opportunity for deeper biological insights in pharmaceutical research using repeated, deep profiling of the same cohorts of patients. Jonathan also explores how advancements in computational approaches allow Sapient to build a robust data foundation for insight generation in biopharma. What You'll Learn in This Episode: The significance of longitudinal patient samplingWhy we need robust conclusions in biotechnology How the role of the FDA is evolving for drug approval and personalized medicine applications Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Sapient Connect with Dr. Jonathan Usuka on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!

How AI Can Increase Clinical Trial Efficiency with Patrick Leung from Faro Health

Mar 19, 2025 39 min

How can AI improve clinical trials and accelerate drug development? In this episode of Data in Biotech, Ross Katz sits down with Patrick Leung, CTO of Faro Health, to explore how AI-driven tools are reshaping clinical trial design. Patrick shares insights into document generation, patient burden analysis, and AI governance in biotech. Learn how Faro Health is developing clinical protocols and leveraging AI to optimize trial success while ensuring regulatory compliance. Whether you're in biotech or healthcare, this conversation offers valuable takeaways on the future of AI in increasing clinical trial efficiency. What You'll Learn in This Episode: How AI is used to generate clinical trial protocols and reduce inefficiencies.The role of AI in assessing patient burden and optimizing trial designs.How data model development enables specialized biomedical AI workflows.How large language models (LLMs) support clinical trial automation.Future trends in AI-driven clinical trial optimization. Links: Find out more about Faro Health: https://www.farohealth.comConnect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with Patrick Leung on LinkedIn: https://www.linkedin.com/in/puiwah/ Meet Our Guest: Patrick Leung is the Chief Technology Officer at Faro Health, where he leads AI-driven innovations in clinical trial design. With a background in data science and software engineering from companies like Google and Two Sigma, Patrick brings a fresh perspective to life sciences, focusing on optimizing clinical trials through AI and structured data models. About the Host: Ross Katz is the Principal and Data Science Lead at CorrDyn, specializing in applying data science to biotech and healthcare. As the host of Data in Biotech, Ross explores the latest trends and innovations shaping the industry. Enjoying the Show? Visit Faro Health to learn more about AI-driven clinical trial optimization. Don’t forget to rate and review Data in Biotech on App...

Organoids and Active Learning for Chronic Disease with Naren Tallapragada

Mar 5, 2025 50 min

In this episode of Data In Biotech, Ross Katz interviews Naren Tallapragada, CEO and Co-founder of Tessel Bio, about his background in electrical engineering and physics and how personal circumstances led to him pivoting his focus to enter biotech and start Tessel Bio. Naren breaks down Tessel Bio’s unique approach to drug discovery, which involves "reverse engineering" chronic diseases. Instead of starting with a potential drug and testing its effects, they begin with a clear picture of the disease itself—specifically, how it appears and behaves in the body. A key part of their method is using human organoids—tiny, lab-grown versions of human tissues—to closely replicate real diseases and see how different treatments interact with them. This “small data” approach is made substantially more efficient with the addition of active learning. Join us for a fascinating conversation about Tessel Bio’s approach to finding cures for chronic diseases that impact hundreds of thousands of people every day. What You'll Learn in This Episode: Naren’s journey into biotech and personal motivationUnderstanding Tessel Bio's approach to drug discoveryThe role of organoids in disease modelingData gathering and target identification strategiesActive learning in drug discovery at Tessel Bio Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Tessel Bio Connect with Naren on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!

How Alex Junge from amass is Speeding Up Scientific Breakthroughs with AI

Feb 19, 2025 52 min

In this episode of the Data and Biotech Podcast, host Ross Katz sits down with Alexander Junge, Co-Founder and CTO of amass, to break down how AI is reshaping scientific research in life sciences. Alex walks us through how his platform is creating professional tools for researchers, biotech companies, and venture firms to navigate the (rapidly!) growing breadth and depth of scientific knowledge by leveraging artificial intelligence - and what this will look like in the future. Alex also shares insights into his company’s work with Nordic Bio Ventures and how amass delivers reliability and builds trust in its platform. What You'll Learn in This Episode: What challenges researchers face in formulating questions and retrieving relevant answers from the breadth of scientific knowledge.The importance of design and user experience in life sciences, and how the company adopts a rigorous approach to information retrieval. How amass helps life sciences professionals navigate complex scientific domains by building trust in answers generated by AI. A real-world case study of how amass is assisting Nordic BioVentures a venture firm to build a biotech company.Alex’s predictions for AI's impact on scientific discovery over the next decade. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about amassConnect with Alex on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!

Advancing Therapeutic Design in Gene and Cell Therapy with Dipen Sangurdekar

Feb 10, 2025 40 min

In this episode of Data in Biotech, Ross sits down with Dipen Sangurdekar, VP of Data Sciences at KSQ Therapeutics, to discuss the role of data-driven approaches in therapeutic design and development. The conversation explores the intersection of computational biology, machine learning, and bioinformatics in advancing personalized medicine and improving patient outcomes. Dipen shares his journey in the industry, emphasizing the importance of integrating data science with biological research and the challenges associated with working in the rapidly evolving field of cell therapies. From hypothesis-driven research to leveraging multimodal data for actionable insights, this episode explores the nuances of using statistical methods and AI to enhance drug development. Key Takeaways: Successful data science in therapeutics requires a deep understanding of both statistical methods and biological processes.High-dimensional but low-sample-size data demands a guided hypothesis-driven approach to avoid false positives.Data integration and collaboration between computational and biological teams are critical for generating meaningful insights.Emerging AI and machine learning tools are enhancing productivity but must be carefully applied in therapeutic research.Picking a problem you’re passionate about and going deep into it is crucial for long-term success in the field. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about KSQ Therapeutics Connect with Dipen on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!

Democratizing Therapeutic Discovery for Neglected Diseases using AI with Timothy Jenkins of DTU Bioengineering

Jan 22, 2025 50 min

This week on Data in Biotech, we welcome Timothy Jenkins, the Head of Data Science and Associate Professor at DTU Bioengineering, a leading scientific community dedicated to advancing areas of biotechnology, food technology, and health through innovative teaching and research. Timothy starts the conversation by walking us through his background and early career beginnings, from the first time he expressed interest in zoology and venomous snakes to now leading a research group focused on AI-guided drug discovery for snake antivenom. He and our host, Ross Katz, dive into one of DTU’s most exciting recent publications about "de novo" designed proteins to neutralize lethal snake venom toxins. Inspired by Nobel Prize winner David Baker’s groundbreaking paper and in collaboration with the Baker Lab on computational design methodology, this project holds great promise in therapeutic discovery and drug development. Tim explains how computational protein design and protein structure prediction are revolutionizing his field, highlighting compelling examples and milestones from his research on antivenom. He also provides an overview of the process used to discover new antivenoms, including the sourcing of biological data, model training, and integration of experimental feedback. Finally, we get Tim’s perspective on the future of AI-powered therapeutic discovery, and his take on the integration of quantum computing into protein design. Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in the life sciences. Useful Links Nature - De novo designed proteins neutralize lethal snake venom toxins Timothy’s LinkedIn DTU Bioengineering Website UW Institute for Protein Design “de novo” designed proteins project Information on Nobel Prize winner David Baker

Revolutionizing Drug Discovery with AI: Fred Manby of Iambic Therapeutics

Jan 8, 2025 38 min

In this episode, Ross Katz sits down with Fred Manby, Co-Founder and Chief Technology Officer of Iambic Therapeutics, to explore how cutting-edge AI technologies are reshaping the landscape of drug discovery. From building advanced machine learning platforms to designing user-friendly interfaces for scientists, Fred shares insights into the company’s approach to tackling some of the biggest challenges in biotech. Fred dives into the unique capabilities of Iambic’s Enchant multi-modal transformer model, its differentiation from other biological foundation models, and the importance of aligning model architecture with data creation and acquisition in modern drug discovery. We also discuss Iambic’s data-driven approach to developing oncology drugs, the exciting possibilities of incorporating new modalities like imaging, and the recent breakthroughs in protein-ligand structure prediction with NeuralPLexer3. Highlights: Enchant Multi-Modal Transformer Model: How it systematically surpasses state-of-the-art molecular AI technologies.Uncertainty Quantification: The role of probabilities and predictions in streamlining drug discovery. Interface Design for Scientists: Iambic’s approach to integration between AI platforms and experimental workflows. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Iambic’s work on their website Connect with Fred Manby on LinkedIn

Unlocking the Power of AI in Microscopy with Ilya Goldberg and Reese Findley

Dec 11, 2024 47 min

In this episode of Data in Biotech, Ross Katz explores the transformative role of AI in microscopic imaging and life sciences with Ilya Goldberg, Chief Science Officer, and Reese Findley, an AI Data Scientist at ViQi. They discuss the cutting-edge applications of AI in automating high-content screening (HCS), enabling more efficient drug discovery, and unraveling complex biological processes. From streamlining time-course analysis to detecting off-target effects in drug compounds, ViQi’s tools are revolutionizing how scientists approach image-based data. Key Highlights: How AI-powered "eyes" analyze thousands of microscopy images to identify phenotypic changes.The benefits of using brightfield imaging and live-cell dyes to capture time-course data efficiently.Real-world applications of AutoHCS for high-content screening, including drug efficacy studies, stem cell differentiation tracking, and phenotypic clustering for toxicity detection.Insights into how automation empowers researchers by reducing repetitive tasks and enhancing focus on innovation.The broader implications of AI in medicine, from radiology to pathology, and how it's redefining workflows for specialists. Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in the life sciences. Learn more about who was featured on the podcast: CorrDyn, an enterprise data specialist that enables excellent companies to make smarter strategic decisions, at www.corrdyn.com ViQi – helping virologists accelerate, automate and simplify infectivity assays: www.viqiai.com Connect with Reese and Ilya on LinkedIn

See all 81 episodes

–

0 ratings from members

Rate this podcast

No reviews yet — be the first member to rate "Data in Biotech".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Blind Tests, Compliance Templates, and Design Over Prediction: Inside AION Labs

Share this podcast

Live Chart rankings

Chart history

🇰🇷 Life Sciences Best #6

Holding at #6 — the line fills in as this chart moves.

🇰🇷 Science Best #32

Podcast details

Created by: CorrDyn
Status: Active
Latest episode: Nov 3, 2026
Episodes: 81
Release period: Every two weeks
Avg. episode length: 45 min
Explicit: No
Language: English

Links

Official website ↗ Apple Podcasts ↗ RSS feed ↗

Is this your podcast?

Claim it to show it on your profile. Using the email from your RSS feed approves it instantly.

Keep listening

Discover more podcasts like this.

Browse podcasts See the charts